Sanofi

Nasdaq SNY · Paris, France

Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health

Sanofi is a clinical trial sponsor based in Paris, France, listed as Nasdaq SNY. It has 156 active clinical trials with 472,094 planned participants, across 17 therapeutic areas. Since 2021 it has completed 281 trials and stopped 83 early.

Trial track record · since 2021

156Active trials472,094 planned participants
281Completed137 with results posted
83Stopped early23% of finished trials

Financials · Nasdaq SNY

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Fundraising

Pipeline · 156 active trials

StageTrialStatus

On the market

1 approved drug application with a product on the market.

Questions about Sanofi

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-11-06.

Approve Suite is not affiliated with Sanofi.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.